Publications by Fredrik Hellem Schjesvold

74 publications found

Publications 2023

  1. Bach-Gansmo T, Hodt A, Schjesvold FH, Gude E, Wien TN (2023)
    Bone scintigraphy reduces the need for biopsy in suspected cardiac amyloidosis
    Tidsskr Nor Laegeforen, 143 (9)
    DOI 10.4045/tidsskr.22.0644, PubMed 37341415
  2. Groen K, Schjesvold FH, van der Holt B, Levin MD, Seefat MR, Hansson M, Leys MBL, Regelink JC, Waage A, Szatkowski D, Axelsson P, Hieu Do T, Svirskaite A, van der Spek E, Haukas E, Knut-Bojanowska D, Ypma PF, Blimark CH, Mellqvist UH, van de Donk NWCJ, Sonneveld P, Klostergaard A, Vangsted AJ, Abildgaard N, Zweegman S (2023)
    Ixazomib-Thalidomide-Dexamethasone Induction Followed by Ixazomib or Placebo Maintenance in Nontransplant Eligible Newly Diagnosed Multiple Myeloma Patients: Long-term Results of HOVON-126/NMSG 21.13
    Hemasphere, 7 (9), e940
    DOI 10.1097/HS9.0000000000000940, PubMed 37663673
  3. Gundesen MT, Asmussen JT, Schjesvold F, Vangsted AJ, Helleberg C, Haukås E, Silkjær T, Teodorescu EM, Jensen BA, Slørdahl TS, Nahi H, Waage A, Abildgaard N, Lund T, Nordic Myeloma Study Group (2023)
    Potential value of pre-planned imaging of bone disease in multiple myeloma
    Blood Cancer J, 13 (1), 105
    DOI 10.1038/s41408-023-00880-0, PubMed 37419876
  4. Köhn-Luque A, Myklebust EM, Tadele DS, Giliberto M, Schmiester L, Noory J, Harivel E, Arsenteva P, Mumenthaler SM, Schjesvold F, Taskén K, Enserink JM, Leder K, Frigessi A, Foo J (2023)
    Phenotypic deconvolution in heterogeneous cancer cell populations using drug-screening data
    Cell Rep Methods, 3 (3), 100417
    DOI 10.1016/j.crmeth.2023.100417, PubMed 37056380
  5. Ludwig H, Terpos E, van de Donk N, Mateos MV, Moreau P, Dimopoulos MA, Delforge M, Rodriguez-Otero P, San-Miguel J, Yong K, Gay F, Einsele H, Mina R, Caers J, Driessen C, Musto P, Zweegman S, Engelhardt M, Cook G, Weisel K, Broijl A, Beksac M, Bila J, Schjesvold F, Cavo M et al. (2023)
    Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network
    Lancet Oncol, 24 (6), e255-e269
    DOI 10.1016/S1470-2045(23)00159-6, PubMed 37269857
  6. Nørgaard JN, Abildgaard N, Lysén A, Tsykunova G, Vangsted AJ, João C, Remen N, Nielsen LK, Osnes L, Stokke C, Connelly JP, Revheim MR, Nordic Myeloma Study Group (NMSG), Schjesvold F (2023)
    Intensifying treatment in PET-positive multiple myeloma patients after upfront autologous stem cell transplantation
    Leukemia, 37 (10), 2107-2114
    DOI 10.1038/s41375-023-01998-7, PubMed 37568010
  7. Plesner T, Harrison SJ, Quach H, Lee C, Bryant A, Vangsted A, Estell J, Delforge M, Offner F, Twomey P, Choeurng V, Li J, Hendricks R, Ruppert SM, Sumiyoshi T, Miller K, Cho E, Schjesvold F (2023)
    Phase I Study of Safety and Pharmacokinetics of RO7297089, an Anti-BCMA/CD16a Bispecific Antibody, in Patients with Relapsed, Refractory Multiple Myeloma
    Clin Hematol Int, 5 (1), 43-51
    DOI 10.1007/s44228-022-00023-5, PubMed 36656461
  8. Pour L, Szarejko M, Bila J, Schjesvold FH, Spicka I, Maisnar V, Jurczyszyn A, Grudeva-Popova Z, Hájek R, Usenko G, Thuresson M, Norin S, Jarefors S, Bakker NA, Richardson PG, Mateos MV (2023)
    Efficacy and safety of melflufen plus daratumumab and dexamethasone in relapsed/refractory multiple myeloma: results from the randomized, open-label, phase III LIGHTHOUSE study
    Haematologica (in press)
    DOI 10.3324/haematol.2023.283509, PubMed 37646660
  9. Raab MS, Cohen YC, Schjesvold F, Aardalen K, Oka A, Spencer A, Wermke M, Souza AD, Kaufman JL, Cafro AM, Ocio EM, Doki N, Henson K, Trabucco G, Carrion A, Bender FC, Juif PE, Fessehatsion A, Fan L, Stonehouse JP, Blankenship JW, Granda B, De Vita S, Lu H (2023)
    Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody
    Leukemia, 37 (6), 1349-1360
    DOI 10.1038/s41375-023-01883-3, PubMed 37024520
  10. Raab MS, Zamagni E, Manier S, Rodriguez-Otero P, Schjesvold F, Broijl A (2023)
    Difficult-to-treat patients with relapsed/refractory multiple myeloma: A review of clinical trial results
    EJHaem, 4 (4), 1117-1131
    DOI 10.1002/jha2.743, PubMed 38024633
  11. Schjesvold FH, Ludwig H, Mateos MV, Larocca A, Abdulhaq H, Norin S, Thuresson M, Bakker NA, Richardson PG, Sonneveld P (2023)
    Melflufen in relapsed/refractory multiple myeloma refractory to prior alkylators: A subgroup analysis from the OCEAN study
    Eur J Haematol (in press)
    DOI 10.1111/ejh.14127, PubMed 37968873
  12. Sonneveld P, Richardson PG, Ludwig H, Dimopoulos MA, Schjesvold FH, Hájek R, Abdulhaq H, Thuresson M, Norin S, Bakker NA, Mateos MV (2023)
    Benefit Versus Risk Assessment of Melflufen and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Analyses From Longer Follow-up of the OCEAN and HORIZON Studies
    Clin Lymphoma Myeloma Leuk, 23 (9), 687-696
    DOI 10.1016/j.clml.2023.05.004, PubMed 37355418
  13. Terpos E, Musto P, Engelhardt M, Delforge M, Cook G, Gay F, van de Donk NWCJ, Ntanasis-Stathopoulos I, Vangsted AJ, Driessen C, Schjesvold F, Cerchione C, Zweegman S, Hajek R, Moreau P, Einsele H, San-Miguel J, Boccadoro M, Dimopoulos MA, Sonneveld P, Ludwig H (2023)
    Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
    Leukemia, 37 (6), 1175-1185
    DOI 10.1038/s41375-023-01920-1, PubMed 37142661
  14. van de Donk NWCJ, Minnema MC, van der Holt B, Schjesvold F, Wu KL, Broijl A, Roeloffzen WWH, Gadisseur A, Pietrantuono G, Pour L, van der Velden VHJ, Lund T, Offidani M, Grasso M, Giaccone L, Razawy W, Tacchetti P, Mancuso K, Silkjaer T, Caers J, Zweegman S, Hájek R, Benjamin R, Vangsted AJ, Boccadoro M et al. (2023)
    Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study
    Lancet Oncol, 24 (10), 1119-1133
    DOI 10.1016/S1470-2045(23)00405-9, PubMed 37717583

Publications 2022

  1. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U, EHA Guidelines Committee ESMO Guidelines Committee. Electronic address: guidelines@ehaweb.org (2022)
    Corrigendum to "Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up'": [Ann Oncol Volume 33, Issue 1, January 2022, Page 117]
    Ann Oncol, 33 (9), 988
    DOI 10.1016/j.annonc.2022.05.004, PubMed 35810138
  2. Dimopoulos MA, Schjesvold F, Doronin V, Vinogradova O, Quach H, Leleu X, Montes YG, Ramasamy K, Pompa A, Levin MD, Lee C, Mellqvist UH, Fenk R, Demarquette H, Sati H, Vorog A, Labotka R, Du J, Darif M, Kumar S (2022)
    Oral ixazomib-dexamethasone vs oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma: a randomized Phase 2 trial
    Blood Cancer J, 12 (1), 9
    DOI 10.1038/s41408-021-00593-2, PubMed 35075109
  3. Giliberto M, Thimiri Govinda Raj DB, Cremaschi A, Skånland SS, Gade A, Tjønnfjord GE, Schjesvold F, Munthe LA, Taskén K (2022)
    Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically
    Mol Oncol, 16 (6), 1241-1258
    DOI 10.1002/1878-0261.13191, PubMed 35148457
  4. Gundesen MT, Asmussen JT, Haukås E, Schubert M, Abildgaard N, Schjesvold F, Lund T (2022)
    A prospective study of Skeletal survey versus Low-dose whole-body CT for Osteolytic lesions in Multiple Myeloma
    Eur J Haematol, 108 (5), 423-429
    DOI 10.1111/ejh.13749, PubMed 35113466
  5. Janssens R, Lang T, Vallejo A, Galinsky J, Morgan K, Plate A, De Ronne C, Verschueren M, Schoefs E, Vanhellemont A, Delforge M, Schjesvold F, Cabezudo E, Vandebroek M, Stevens H, Simoens S, Huys I (2022)
    What matters most to patients with multiple myeloma? A Pan-European patient preference study
    Front Oncol, 12, 1027353
    DOI 10.3389/fonc.2022.1027353, PubMed 36523996
  6. Leleu X, Martin T, Weisel K, Schjesvold F, Iida S, Malavasi F, Manier S, Chang-Ki Min, Ocio EM, Pawlyn C, Perrot A, Quach H, Richter J, Spicka I, Yong K, Richardson PG (2022)
    Anti-CD38 antibody therapy for patients with relapsed/refractory multiple myeloma: differential mechanisms of action and recent clinical trial outcomes
    Ann Hematol, 101 (10), 2123-2137
    DOI 10.1007/s00277-022-04917-5, PubMed 35943588
  7. Ocio EM, Nadeem O, Schjesvold F, Gay F, Touzeau C, Dimopoulos MA, Richardson PG, Mateos MV (2022)
    Melflufen for the treatment of multiple myeloma
    Expert Rev Clin Pharmacol, 15 (4), 371-382
    DOI 10.1080/17512433.2022.2075847, PubMed 35723075
  8. Richardson PG, Perrot A, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Malinge L, Dubin F, van de Velde H, Anderson KC (2022)
    Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
    Lancet Oncol, 23 (3), 416-427
    DOI 10.1016/S1470-2045(22)00019-5, PubMed 35151415
  9. Schjesvold F, Paiva B, Ribrag V, Rodriguez-Otero P, San-Miguel JF, Robak P, Hansson M, Onishi M, Hamidi H, Malhi V, Dail M, Javery A, Ku G, Raab MS (2022)
    Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma
    Clin Lymphoma Myeloma Leuk, 23 (1), e59-e70
    DOI 10.1016/j.clml.2022.10.006, PubMed 36450626
  10. Schjesvold F, Richardson PG, Facon T, Alegre A, Spencer A, Jurczyszyn A, Sunami K, Frenzel L, Min CK, Guillonneau S, Lin PL, Le-Guennec S, Campana F, Van de Velde H, Bensfia S, Bringhen S (2022)
    Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
    Haematologica, 107 (3), 774-775
    DOI 10.3324/haematol.2021.279160, PubMed 35229573
  11. Schjesvold FH, Bakker NA, Sonneveld P (2022)
    Melflufen in multiple myeloma: the conclusion matters - Authors' reply
    Lancet Haematol, 9 (4), e244-e245
    DOI 10.1016/S2352-3026(22)00071-0, PubMed 35358436
  12. Schjesvold FH, Bakker NA, Sonneveld P (2022)
    Authors' reply: Perspective: The approval and withdrawal of melphalan flufenamide (melflufen): Implications for the state of the FDA
    Transl Oncol, 25, 101528
    DOI 10.1016/j.tranon.2022.101528, PubMed 36087383
  13. Schjesvold FH, Dimopoulos MA, Delimpasi S, Robak P, Coriu D, Legiec W, Pour L, Špička I, Masszi T, Doronin V, Minarik J, Salogub G, Alekseeva Y, Lazzaro A, Maisnar V, Mikala G, Rosiñol L, Liberati AM, Symeonidis A, Moody V, Thuresson M, Byrne C, Harmenberg J, Bakker NA, Hájek R et al. (2022)
    Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study
    Lancet Haematol, 9 (2), e98-e110
    DOI 10.1016/S2352-3026(21)00381-1, PubMed 35032434
  14. Schmitz A, Brøndum RF, Johnsen HE, Mellqvist UH, Waage A, Gimsing P, Op Bruinink DH, van der Velden V, van der Holt B, Hansson M, Andersen NF, Frølund UC, Helleberg C, Schjesvold FH, Ahlberg L, Gulbrandsen N, Andreasson B, Lauri B, Haukas E, Bødker JS, Roug AS, Bøgsted M, Severinsen MT, Gregersen H, Abildgaard N et al. (2022)
    Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission - results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial
    BMC Cancer, 22 (1), 147
    DOI 10.1186/s12885-022-09184-1, PubMed 35123422
  15. Stokke C, Nørgaard JN, Feiring Phillips H, Sherwani A, Nuruddin S, Connelly J, Schjesvold F, Revheim ME (2022)
    Comparison of [18F]fluciclovine and [18F]FDG PET/CT in Newly Diagnosed Multiple Myeloma Patients
    Mol Imaging Biol, 24 (5), 842-851
    DOI 10.1007/s11307-022-01734-0, PubMed 35501622

Publications 2021

  1. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U (2021)
    Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up
    Hemasphere, 5 (2), e528
    DOI 10.1097/HS9.0000000000000528, PubMed 33554050
  2. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U, EHA Guidelines Committee ESMO Guidelines Committee. Electronic address: guidelines@ehaweb.org (2021)
    Corrigendum to 'Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up': [Ann Oncol 2021; 32(3): 309-322]
    Ann Oncol, 33 (1), 117
    DOI 10.1016/j.annonc.2021.10.001, PubMed 34857439
  3. Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G, Delforge M, Hájek R, Schjesvold F, Cavo M, Goldschmidt H, Facon T, Einsele H, Boccadoro M, San-Miguel J, Sonneveld P, Mey U, EHA Guidelines Committee. Electronic address: guidelines@ehaweb.org, ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org (2021)
    Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
    Ann Oncol, 32 (3), 309-322
    DOI 10.1016/j.annonc.2020.11.014, PubMed 33549387
  4. Fernández de Larrea C, Kyle R, Rosiñol L, Paiva B, Engelhardt M, Usmani S, Caers J, Gonsalves W, Schjesvold F, Merlini G, Lentzch S, Ocio E, Garderet L, Moreau P, Sonneveld P, Badros A, Gahrton G, Goldschmidt H, Tuchman S, Einsele H, Durie B, Wirk B, Musto P, Hayden P, Kaiser M et al. (2021)
    Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage
    Blood Cancer J, 11 (12), 192
    DOI 10.1038/s41408-021-00587-0, PubMed 34857730
  5. Gregersen H, Peceliunas V, Remes K, Schjesvold F, Abildgaard N, Nahi H, Andersen NF, Vangsted AJ, Klausen TW, Helleberg C, Carlson K, Frølund UC, Axelsson P, Stromberg O, Blimark CH, Crafoord J, Tsykunova G, Eshoj HR, Waage A, Hansson M, Gulbrandsen N (2021)
    Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: A randomised phase 2 trial by the Nordic Myeloma Study Group
    Eur J Haematol, 108 (1), 34-44
    DOI 10.1111/ejh.13709, PubMed 34536308
  6. Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de la Fuente FA, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA (2021)
    Correction to: Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
    Ann Hematol, 100 (1), 297-302
    DOI 10.1007/s00277-020-04302-0, PubMed 33106909
  7. Kaufman JL, Gasparetto C, Schjesvold FH, Moreau P, Touzeau C, Facon T, Boise LH, Jiang Y, Yang X, Dunbar F, Vishwamitra D, Unger S, Macartney T, Pesko J, Yu Y, Salem AH, Ross JA, Hong WJ, Maciag PC, Pauff JM, Kumar S (2021)
    Targeting BCL-2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma
    Am J Hematol, 96 (4), 418-427
    DOI 10.1002/ajh.26083, PubMed 33368455
  8. Ludwig H, Sonneveld P, Facon T, San-Miguel J, Avet-Loiseau H, Mohty M, Mateos MV, Moreau P, Cavo M, Pawlyn C, Zweegman S, Engelhardt M, Driessen C, Cook G, Dimopoulos MA, Gay F, Einsele H, Delforge M, Caers J, Weisel K, Jackson G, Garderet L, van de Donk N, Leleu X, Goldschmidt H et al. (2021)
    COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
    Lancet Haematol, 8 (12), e934-e946
    DOI 10.1016/S2352-3026(21)00278-7, PubMed 34756169
  9. Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, Ludwig H, Mikhael J, Terpos E, Schjesvold F, Martin T, Yong K, Durie BGM, Facon T, Jurczyszyn A, Sidana S, Raje N, van de Donk N, Lonial S, Cavo M, Kristinsson SY, Lentzsch S, Hajek R, Anderson KC, João C et al. (2021)
    Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group
    Lancet Oncol, 22 (3), e105-e118
    DOI 10.1016/S1470-2045(20)30756-7, PubMed 33662288
  10. Richardson PG, Harrison SJ, Bringhen S, Schjesvold F, Yong K, Campana F, Le-Guennec S, Macé S, Dimopoulos MA (2021)
    Isatuximab for relapsed/refractory multiple myeloma: review of key subgroup analyses from the Phase III ICARIA-MM study
    Future Oncol, 17 (34), 4797-4812
    DOI 10.2217/fon-2021-0568, PubMed 34521277
  11. Richardson PG, Schjesvold F, Weisel K, Moreau P, Anderson LD, White D, Rodriguez-Otero P, Sonneveld P, Engelhardt M, Jenner M, Corso A, Dürig J, Pavic M, Salomo M, Beksac M, Oriol A, Lindsay J, Liberati AM, Galli M, Robak P, Larocca A, Yagci M, Vural F, Kanate AS, Jiang R et al. (2021)
    Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide-pretreated myeloma: A subanalysis of OPTIMISMM by clinical characteristics
    Eur J Haematol, 108 (1), 73-83
    DOI 10.1111/ejh.13706, PubMed 34496096
  12. Schjesvold F, Bringhen S, G Richardson P, Perrot A, Leleu X, Moreau P, A Dimopoulos M, Hulin C, Tekle C, Foster MC, Poole EM, van de Velde H, Facon T (2021)
    Isatuximab plus pomalidomide and dexamethasone in frail patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
    Am J Hematol, 96 (11), E423-E427
    DOI 10.1002/ajh.26319, PubMed 34383345
  13. Schjesvold F, Oriol A (2021)
    Current and Novel Alkylators in Multiple Myeloma
    Cancers (Basel), 13 (10)
    DOI 10.3390/cancers13102465, PubMed 34070213
  14. Schjesvold FH, Richardson PG, Facon T, Alegre A, Spencer A, Jurczyszyn A, Sunami K, Frenzel L, Min CK, Guillonneau S, Lin PL, Le-Guennec S, Campana F, van de Velde H, Bensfia S, Bringhen S (2021)
    Isatuximab plus pomalidomide and dexamethasone in elderly patients with relapsed/refractory multiple myeloma: ICARIA-MM subgroup analysis
    Haematologica, 106 (4), 1182-1187
    DOI 10.3324/haematol.2020.253450, PubMed 32586908
  15. Terpos E, Zamagni E, Lentzsch S, Drake MT, García-Sanz R, Abildgaard N, Ntanasis-Stathopoulos I, Schjesvold F, de la Rubia J, Kyriakou C, Hillengass J, Zweegman S, Cavo M, Moreau P, San-Miguel J, Dimopoulos MA, Munshi N, Durie BGM, Raje N, Bone Working Group of the International Myeloma Working Group (2021)
    Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group
    Lancet Oncol, 22 (3), e119-e130
    DOI 10.1016/S1470-2045(20)30559-3, PubMed 33545067
  16. Tjonnfjord GE, Schjesvold FH, Gulbrandsen N, Kvam AK (2021)
    Monoclonal gammopathy of clinical importance
    Tidsskr. Nor. Laegeforen., 141 (13), 1276-1280
  17. Tjønnfjord GE, Schjesvold FH, Gulbrandsen N, Kvam AK (2021)
    [Monoclonal gammopathy of clinical importance]
    Tidsskr Nor Laegeforen, 141 (2021-13)
    DOI 10.4045/tidsskr.20.0981, PubMed 34596996
  18. Walladbegi J, Henriksson R, Tavelin B, Svanberg A, Larfors G, Jädersten M, Schjesvold F, Mahdi A, Garming Legert K, Peterson DE, Jontell M (2021)
    Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial
    Bone Marrow Transplant, 57 (2), 191-197
    DOI 10.1038/s41409-021-01512-6, PubMed 34728786

Publications 2020

  1. Kaiser M, Beksaç M, Gulbrandsen N, Schjesvold F, Hájek R, Moreau P, de Arriba de la Fuente F, Mateos MV, West S, Spencer A, Rajkumar SV, Suryanarayan K, Czorniak M, Li C, Teng Z, Labotka R, Dimopoulos MA (2020)
    Adverse event management in the TOURMALINE-MM3 study of post-transplant ixazomib maintenance in multiple myeloma
    Ann Hematol, 99 (8), 1793-1804
    DOI 10.1007/s00277-020-04149-5, PubMed 32613281
  2. Laubach JP, Schjesvold F, Mariz M, Dimopoulos MA, Lech-Maranda E, Spicka I, Hungria VTM, Shelekhova T, Abdo A, Jacobasch L, Polprasert C, Hájek R, Illés Á, Wróbel T, Sureda A, Beksac M, Gonçalves IZ, Bladé J, Rajkumar SV, Chari A, Lonial S, Spencer A, Maison-Blanche P, Moreau P, San-Miguel JF et al. (2020)
    Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study
    Lancet Oncol, 22 (1), 142-154
    DOI 10.1016/S1470-2045(20)30680-X, PubMed 33301738
  3. Oriol A, Larocca A, Leleu X, Hajek R, Hassoun H, Rodríguez-Otero P, Paner A, Schjesvold FH, Gullbo J, Richardson PG (2020)
    Melflufen for relapsed and refractory multiple myeloma
    Expert Opin Investig Drugs, 29 (10), 1069-1078
    DOI 10.1080/13543784.2020.1808884, PubMed 32924646
  4. Schjesvold F (2020)
    Evolution of diagnostic workup and treatment for multiple myeloma 2013-2019
    Eur J Haematol, 105 (4), 434-448
    DOI 10.1111/ejh.13464, PubMed 32557833
  5. Schjesvold F, Goldschmidt H, Maisnar V, Spicka I, Abildgaard N, Rowlings P, Cain L, Romanus D, Suryanarayan K, Rajkumar V, Odom D, Gnanasakthy A, Dimopoulos M (2020)
    Quality of life is maintained with ixazomib maintenance in post-transplant newly diagnosed multiple myeloma: The TOURMALINE-MM3 trial
    Eur J Haematol, 104 (5), 443-458
    DOI 10.1111/ejh.13379, PubMed 31880006
  6. Schjesvold F, Robak P, Pour L, Aschan J, Sonneveld P (2020)
    OCEAN: a randomized Phase III study of melflufen + dexamethasone to treat relapsed refractory multiple myeloma
    Future Oncol, 16 (11), 631-641
    DOI 10.2217/fon-2020-0024, PubMed 32141766
  7. Zweegman S, Stege CAM, Haukas E, Schjesvold FH, Levin MD, Waage A, Leys RBL, Klein SK, Szatkowski D, Axelsson P, Hieu Do T, Knut-Bojanowska D, van der Spek E, Svirskaite A, Klostergaard A, Salomo M, Blimark C, Ypma PF, Mellqvist UH, Poddighe PJ, Stevens-Kroef M, van de Donk NWCJ, Sonneveld P, Hansson M, van der Holt B et al. (2020)
    Ixazomib-Thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; results from the randomized phase II HOVON-126/NMSG 21.13 trial
    Haematologica, 105 (12), 2879-2882
    DOI 10.3324/haematol.2019.240374, PubMed 33256392

Publications 2019

  1. Attal M, Richardson PG, Rajkumar SV, San-Miguel J, Beksac M, Spicka I, Leleu X, Schjesvold F, Moreau P, Dimopoulos MA, Huang JS, Minarik J, Cavo M, Prince HM, Macé S, Corzo KP, Campana F, Le-Guennec S, Dubin F, Anderson KC, ICARIA-MM study group (2019)
    Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study
    Lancet, 394 (10214), 2096-2107
    DOI 10.1016/S0140-6736(19)32556-5, PubMed 31735560
  2. Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H et al. (2019)
    International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
    Lancet Oncol, 20 (6), e302-e312
    DOI 10.1016/S1470-2045(19)30309-2, PubMed 31162104
  3. Mateos MV, Blacklock H, Schjesvold F, Oriol A, Simpson D, George A, Goldschmidt H, Larocca A, Chanan-Khan A, Sherbenou D, Avivi I, Benyamini N, Iida S, Matsumoto M, Suzuki K, Ribrag V, Usmani SZ, Jagannath S, Ocio EM, Rodriguez-Otero P, San Miguel J, Kher U, Farooqui M, Liao J, Marinello P et al. (2019)
    Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial
    Lancet Haematol, 6 (9), e459-e469
    DOI 10.1016/S2352-3026(19)30110-3, PubMed 31327687
  4. Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M et al. (2019)
    Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial
    Lancet Oncol, 20 (6), 781-794
    DOI 10.1016/S1470-2045(19)30152-4, PubMed 31097405
  5. Usmani SZ, Schjesvold F, Oriol A, Karlin L, Cavo M, Rifkin RM, Yimer HA, LeBlanc R, Takezako N, McCroskey RD, Lim ABM, Suzuki K, Kosugi H, Grigoriadis G, Avivi I, Facon T, Jagannath S, Lonial S, Ghori RU, Farooqui MZH, Marinello P, San-Miguel J, KEYNOTE-185 Investigators (2019)
    Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
    Lancet Haematol, 6 (9), e448-e458
    DOI 10.1016/S2352-3026(19)30109-7, PubMed 31327689

Publications 2018

  1. Dimopoulos MA, Gay F, Schjesvold F, Beksac M, Hajek R, Weisel KC, Goldschmidt H, Maisnar V, Moreau P, Min CK, Pluta A, Chng WJ, Kaiser M, Zweegman S, Mateos MV, Spencer A, Iida S, Morgan G, Suryanarayan K, Teng Z, Skacel T, Palumbo A, Dash AB, Gupta N, Labotka R et al. (2018)
    Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
    Lancet, 393 (10168), 253-264
    DOI 10.1016/S0140-6736(18)33003-4, PubMed 30545780
  2. Tangen JM, Tjønnfjord GE, Gulbrandsen N, Gedde-Dahl T, Stormorken E, Anderson K, Vo CD, Schjesvold FH, For Oslo Myeloma Center (2018)
    Improved outcome in patients following autologous stem cell transplantation for multiple myeloma in south eastern Norway 2001-2010: a retrospective, population based analysis
    BMC Cancer, 18 (1), 801
    DOI 10.1186/s12885-018-4722-x, PubMed 30089450
  3. Thimiri Govinda Raj DB, Cremaschi A, Skånland SS, Gade A, Schjesvold FH, Tjønnfjord GE, Munthe LA, Tasken K (2018)
    In-Vitro Drug Sensitivity Screening in Chronic Lymphocytic Leukemia (CLL) Primary Patient Samples Identifies Drug Candidates for Precision Cancer Therapy
    Blood, 132, 4676
    DOI 10.1182/blood-2018-99-110357, PublikaID 304
  4. Thimiri Govinda Raj DB, Giliberto M, Cremaschi A, Skånland SS, Gade A, Tjønnfjord GE, Schjesvold FH, Munthe LA, Tasken K (2018)
    Drug Sensitivity Screening on Multiple Myeloma for Precision Cancer Therapy
    Blood, 132, 4677
    DOI 10.1182/blood-2018-99-110669, PublikaID 303

Publications 2017

  1. Schjesvold FH (2017)
    [Not Available]
    Tidsskr Nor Laegeforen, 137 (1), 58
    DOI 10.4045/tidsskr.16.0963, PubMed 28073239
  2. Wang D, Fløisand Y, Myklebust CV, Bürgler S, Parente-Ribes A, Hofgaard PO, Bogen B, Taskén K, Tjønnfjord GE, Schjesvold F, Dalgaard J, Tveita A, Munthe LA (2017)
    Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice
    Leukemia, 31 (10), 2114-2121
    DOI 10.1038/leu.2017.69, PubMed 28232741

Publications 2016

  1. Torfoss D, Fladhagen T, Holte H, Brinch L, Schjesvold FH, Fløisand Y, Nyquist E, Dalgaard J, Meyer P, Lehmann AK, Hammerstrøm J, Skjelbakken T, Høiby EA, Sandvik L, Kvaløy S (2016)
    Benzylpenicillin plus an aminoglycoside versus meropenem in neutropenic lymphoma and leukaemia patients with a suspected bacterial infection: a randomized, controlled trial
    Clin Microbiol Infect, 23 (3), 179-187
    DOI 10.1016/j.cmi.2016.10.019, PubMed 27793737

Publications 2015

  1. Tveita AA, Schjesvold F, Haabeth OA, Fauskanger M, Bogen B (2015)
    Tumors Escape CD4+ T-cell-Mediated Immunosurveillance by Impairing the Ability of Infiltrating Macrophages to Indirectly Present Tumor Antigens
    Cancer Res, 75 (16), 3268-78
    DOI 10.1158/0008-5472.CAN-14-3640, PubMed 26038231

Publications 2014

  1. Haabeth OA, Tveita AA, Fauskanger M, Schjesvold F, Lorvik KB, Hofgaard PO, Omholt H, Munthe LA, Dembic Z, Corthay A, Bogen B (2014)
    How Do CD4(+) T Cells Detect and Eliminate Tumor Cells That Either Lack or Express MHC Class II Molecules?
    Front Immunol, 5, 174
    DOI 10.3389/fimmu.2014.00174, PubMed 24782871
  2. Tveita AA, Schjesvold FH, Sundnes O, Haabeth OA, Haraldsen G, Bogen B (2014)
    Indirect CD4+ T-cell-mediated elimination of MHC II(NEG) tumor cells is spatially restricted and fails to prevent escape of antigen-negative cells
    Eur J Immunol, 44 (9), 2625-37
    DOI 10.1002/eji.201444659, PubMed 24846412

Publications 2013

  1. Schjesvold F, Wiencke K, Tjønnfjord GE (2013)
    [Investigation of anemia]
    Tidsskr Nor Laegeforen, 133 (6), 610
    DOI 10.4045/tidsskr.13.0256, PubMed 23552139
  2. Schjesvold FH (2013)
    [Investigation of amyloidosis]
    Tidsskr Nor Laegeforen, 133 (3), 266
    DOI 10.4045/tidsskr.13.0044, PubMed 23381155

Publications 2012

  1. Tazmini K, Bakken HN, Schjesvold FH (2012)
    A woman in her seventies with reduced general condition, dyspnoea and generalised pain
    Tidsskr Nor Laegeforen, 132 (17), 1969-72
    DOI 10.4045/tidsskr.11.0608, PubMed 23007363

Publications 2009

  1. Schjesvold FH (2009)
    [Erythrocytosis as a problem]
    Tidsskr Nor Laegeforen, 129 (22), 2387; author reply 2387
    DOI 10.4045/tidsskr.09.1196, PubMed 19935946

Publications 2008

  1. Schjesvold FH, Sjo M, Tangen JM, Hammerstrøm J, Brinch L (2008)
    [High-dose treatment of systemic AL-amyloidosis with autologous stem cell support]
    Tidsskr Nor Laegeforen, 128 (12), 1392-6
    PubMed 18552900
 
Page visits: 5322
Scroll to top